Navigation Links
RiskMetrics Recommends Taro Shareholders Vote Against Taro Board of Directors
Date:12/24/2009

MUMBAI, India, Dec. 24 /PRNewswire-FirstCall/ -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) today announced that RiskMetrics Group's ISS Governance Services (RMG), a leading independent proxy advisory firm, recommended that shareholders of Taro Pharmaceutical Industries Ltd. (Pink Sheets: TAROF) vote against Taro's board of director nominees for election or re-election as directors, as well as the indemnification proposal for its proposed external directors, in the upcoming Annual General Meeting of Taro's shareholders scheduled for December 31, 2009.

In its report, dated December 23, 2009, RiskMetrics stated that "...with little indication that the company has moved to rectify its continuing problems, and with little information disclosed on the process of solving these problems, RMG now recommends that shareholders reject the entire slate of management candidates." RMG cites the board's "lack of oversight of the financial management of the company, and what has become the routine failure to produce audited financials for the past six years" as reasons why Taro's current board members "do not merit reelection."

Regarding the election of Taro's external director nominees, RMG notes that both nominees "...have past ties to the company" and that "...the existence of these connections raises questions of why a company under such scrutiny would risk the appearance of a lack of independence rather than finding two candidates with no previous ties to the company."

The RiskMetrics report is the third report by an independent proxy advisory firm to recommend Taro shareholders vote against Taro's board of director nominees and vote against Taro's indemnification proposal for its proposed external directors. Glass Lewis and PROXY Governance, Inc. recently issued reports advising shareholders to hold Taro's board accountable for their actions and vote against all of Taro's proposals.

Sun encourages fellow Taro shareholders to follow the professional advice of RiskMetrics, Glass Lewis and PROXY Governance and vote against the re-election of the incumbent directors and their nominees for external directors and against the board's indemnification proposals by signing, dating and returning their proxy cards immediately.

For questions or assistance in voting or changing their votes, Taro shareholders can contact Sun's proxy solicitors, MacKenzie Partners, Inc., within the U.S. and Canada at 1-800-322-2885 (toll-free) or 1-212-929-5500 (call collect), within Israel at +1-809-494-159 (toll-free) or via email at proxy@mackenziepartners.com.

About RiskMetrics

RiskMetrics Group is a leading provider of risk management and corporate governance products and services to participants in the global financial markets. By bringing transparency, expertise and access to the financial markets, RiskMetrics Group helps investors better understand and manage the risks associated with their financial holdings. Our solutions address a broad spectrum of risk across our clients' financial assets. Headquartered in New York with 20 global offices, RiskMetrics Group services some of the most prestigious institutions and corporations worldwide. For more information, please visit, www.riskmetrics.com.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

You can also follow us on Twitter.

Contacts



    Uday Baldota                           Mira Desai
    Tel        +91 22 6645 5645, x 605     Tel        +91 22 6645 5645, x 606
    Tel Direct +91 22 66455605             Tel Direct +91 22 66455606
    Mobile     +91 98670 10529             Mobile     +91 98219 23797
    E mail     uday.baldota@sunpharma.com  E mail     mira.desai@sunpharma.com

    Brunswick Group for Sun Pharma         MacKenzie Partners
    Erin Becker/Nicki Kahner               Robert Marese
    +1 212 333 3810                        +1 212 929 5500

    Arad Communications for Sun Pharma     Greenhill
    Irit Radia                             Ashish Contractor
    +972-54-6699311                        +1 212 389 1537

SOURCE Sun Pharmaceutical Industries Ltd.


'/>"/>
SOURCE Sun Pharmaceutical Industries Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. CHMP Recommends Expanded Use of Angiox(R) (Bivalirudin) in Europe for Patients With Acute Coronary Syndromes
2. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
3. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
4. FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
5. Task Force Recommends Screening for Hearing Loss in All Newborns
6. CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients
7. Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout
8. CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors
9. Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial
10. Task Force Recommends Using Aspirin to Prevent Cardiovascular Disease When the Benefits Outweigh the Harms
11. FDA Advisory Committee Recommends Approval of Multaq(R) (dronedarone)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016 Valeritas Holdings, ... an alternative public offering (APO). This was accomplished via ... Valeritas, Inc. and a private placement of approximately 5 ... per share. Under the terms of the ... Valeritas Holdings, Inc. will trade on the OTC Markets ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Actinic Keratosis Market and ... their offering.       (Logo: ... Market and Competitive Landscape Highlights 2016, provides ... Actinic Keratosis epidemiology, Actinic Keratosis market valuations ...
(Date:5/3/2016)... 2016 Research and Markets has ... Cell Therapy Market Outlook 2020" report to their ... , ,Recombinant technology has improved significantly in past years ... developed in coming years. Many cancer drugs have been ... therapies are also expected to be developed with its ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... ... charity program created to assist the people of their local community. The agency ... organizations and community leaders. Their hope is to bring awareness to important local ...
(Date:5/4/2016)... ... ... Dr. Elyson and Dr. Assili, dentist in Northridge , announce that they ... common dental procedure, is performed for many adolescents and young adults today. While wisdom ... complications. By providing wisdom tooth removal surgery at their office, Dr. Elyson and Dr. ...
(Date:5/4/2016)... ... ... Francesca Loparco, Co-Founder of Queen City Dream Cars, an exotic car rental business ... at Christenbury Eye Center. The entrepreneur struggled with her computer, riding horses and driving ... her in-office consultation and eye exam. Francesca’s eyesight was restored to 20/20 in both ...
(Date:5/4/2016)... ... May 04, 2016 , ... Bayco ... compact tactical (6.7 inch) dual-light flashlights in models NSP-9842XL and NSR-9844XL . ... retail starting at $59.95) uses 2 included CR-123 batteries to produce up to ...
(Date:5/4/2016)... ... May 04, 2016 , ... Warren L. Smith M.D. , There ... UTIs, have plagued people since the beginning of recorded medical history, and in ... every year. It's not just a matter of inconvenience; bladder infections cost us billions ...
Breaking Medicine News(10 mins):